Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05224609 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05224609 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 21 participants.
The verdict
NCT05224609, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Lorlatinib) in health participants. This study is seeking participants who: * Must be male or female of 18 to 75 years of age, inclusive at the time of the study. * Are willing and able to comply with all scheduled visits, treatment plan, and other study procedures. * Have a BMI (body mass index) of 17.5 to 40 kg/m2; and a total body weight \>50 kg (110 lb). * Are capable of giving signed informed consent document. All participants in this study will receive Lorlatinib. Participants will be placed into 1 of 3 cohorts based on their hepatic (liver) function. Participants will take Lorlatinib once by mouth. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective. Participants will take part in this study for up to 35 days.
Interventions
- DRUG Lorlatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2024-08-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05224609
The ClinicalTrials.gov registry entry for NCT05224609 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lorlatinib is the first listed.
NCT05224609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05224609 about?
NCT05224609 is a clinical study titled "A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Lorlatinib) in health participants. This study is seeking participants who: * Must be male or female of 18 to 75 years of age, inclusive at the time of the study. * Are willing and able to comp...
What is the current status of trial NCT05224609?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-04-28. Estimated completion is 2024-08-13.
What interventions are being tested in trial NCT05224609?
The interventions under investigation include: Lorlatinib (DRUG).
Who is sponsoring clinical trial NCT05224609?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.